Changes in Hong Kong stocks | Cinda Biotech (01801) rose more than 3% intraday and seven innovative products including Xinermei® were successfully included in the national medical insurance drug catalogue

Zhitongcaijing · 1d ago

The Zhitong Finance App learned that Cinda Biotech (01801) rose more than 3% in the intraday period. As of press release, it had risen 1.79% to HK$85.4, with a turnover of HK$398 million.

According to news, recently, Cinda Biotech announced that seven innovative products, including Cinda Biotech's Xinermei ® and Xinmeiyue®, have been successfully included in the new “National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalogue (2026). This time, the company's seven innovative drugs were successfully included in the national medical insurance drug catalogue, covering diseases with heavy social burdens such as tumors (bowel cancer, kidney cancer, hematoma), cardiovascular metabolism, and autoimmunity.

According to the announcement, the products included in the national medical insurance drug catalogue for the first time include Xinermei ® (Mashidu peptide injection, GCG/GLP-1 double receptor agonist), Xinmeiyue® (piconcibalizumab injection, IL-23p19 inhibitor), daboxin® (ipimumab N01 injection, CTLA-4 inhibitor), and Vifotai® (quizatinib hydrochloride tablets, type II FLT3 inhibitors); new Indications included in the catalogue include Dabershu ® (cindilizumab injection, anti-PD-1 monoclonal antibody) and jepalil® (pitobutinib tablets, non-covalent BTK inhibitor); Cimpiride® (tolecimab injection, all-human PCSK9 monoclonal antibody) successfully renewed contracts. The new version of the National Medical Insurance Drug Catalogue will be officially implemented on January 1, 2027.